25 results on '"Journeaux, Alexandra"'
Search Results
2. Hemostasis defects underlying the hemorrhagic syndrome caused by mammarenaviruses in a cynomolgus macaque model
- Author
-
Lafoux, Blaise, Baillet, Nicolas, Picard, Caroline, Fourcaud, Gustave, Borges-Cardoso, Virginie, Reynard, Stéphanie, Journeaux, Alexandra, Germain, Clara, Perthame, Emeline, Mateo, Mathieu, Hortion, Jimmy, Carnec, Xavier, Pietrosemoli, Natalia, Moroso, Marie, Lacroix, Orianne, Jourjon, Ophélie, Barron, Stéphane, Vallve, Audrey, Duthey, Aurélie, Jacquot, Frédéric, Barrot, Laura, Dirheimer, Manon, Raoul, Hervé, Nougier, Christophe, and Baize, Sylvain
- Published
- 2023
- Full Text
- View/download PDF
3. A MOPEVAC multivalent vaccine induces sterile protection against New World arenaviruses in non-human primates
- Author
-
Reynard, Stéphanie, Carnec, Xavier, Picard, Caroline, Borges-Cardoso, Virginie, Journeaux, Alexandra, Mateo, Mathieu, Germain, Clara, Hortion, Jimmy, Albrecht, Laure, Perthame, Emeline, Pietrosemoli, Natalia, Vallvé, Audrey, Barron, Stéphane, Duthey, Aurélie, Lacroix, Orianne, Jourjon, Ophélie, Moroso, Marie, Fellmann, Lyne, Moreau, Pierre-Henri, Daniau, Maïlys, Legras-Lachuer, Catherine, Dirheimer, Manon, Carbonnelle, Caroline, Raoul, Hervé, and Baize, Sylvain
- Published
- 2023
- Full Text
- View/download PDF
4. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial
- Author
-
Tschismarov, Roland, Van Damme, Pierre, Germain, Clara, De Coster, Ilse, Mateo, Mathieu, Reynard, Stephanie, Journeaux, Alexandra, Tomberger, Yvonne, Withanage, Kanchanamala, Haslwanter, Denise, Terler, Katherine, Schrauf, Sabrina, Müllner, Matthias, Tauber, Erich, Ramsauer, Katrin, and Baize, Sylvain
- Published
- 2023
- Full Text
- View/download PDF
5. High Seroreactivities to Orthoebolaviruses in Rural Cameroon: A Case-Control Study on Nonhuman Primate Bites and a Cross-sectional Survey in Rural Populations.
- Author
-
Ramassamy, Jill-Léa, Ayouba, Ahidjo, Thaurignac, Guillaume, Ndongo, Chanceline Bilounga, Nnuka, Patrick, Betsem, Edouard, Njouom, Richard, Ngole, Eitel Mpoudi, Vanhomwegen, Jessica, Hoinard, Damien, England, Patrick, Journeaux, Alexandra, Picard, Caroline, Thomas, Damien, Pannetier, Delphine, Baize, Sylvain, Delaporte, Eric, Peeters, Martine, and Gessain, Antoine
- Subjects
EBOLA virus ,VIRAL proteins ,RURAL population ,HEMORRHAGIC fever ,FILOVIRIDAE - Abstract
Background Ebola (EBOV) and Sudan (SUDV) orthoebolaviruses are responsible for lethal hemorrhagic fever outbreaks in humans in Central and West Africa, and in apes that can be at the source of human outbreaks for EBOV. Methods To assess the risk of exposure to orthoebolaviruses through contact with nonhuman primates (NHP), we tested the presence of antibodies against different viral proteins with a microsphere-based multiplex immunoassay in a case-control study on bites from NHPs in forest areas from Cameroon (n = 795) and in cross-sectional surveys from other rural populations (n = 622) of the same country. Results Seroreactivities against at least 2 viral proteins were detected in 13% and 12% of the samples for EBOV and SUDV, respectively. Probability of seroreactivity was not associated with history of NHP bites, but was 3 times higher in Pygmies compared to Bantus. Although no neutralizing antibodies to EBOV and SUDV were detected in a selected series of highly reactive samples, avidity results indicate strong affinity to SUDV antigens. Conclusions The detection of high level of seroreactivities against orthoebolaviruses in rural Cameroon, where no outbreaks have been reported, raises the possibilities of silent circulation of orthoebolaviruses, or of other not yet documented filoviruses, in these forested regions. Article's main point Our study found high seroreactivities to Ebola and Sudan orthoebolavirus antigens in rural Cameroonian populations, especially among Pygmies, despite no reported outbreaks. This suggests potential silent circulation of orthoebolaviruses or unknown filoviruses, highlighting the need for further surveillance and research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques
- Author
-
Baillet, Nicolas, Reynard, Stéphanie, Perthame, Emeline, Hortion, Jimmy, Journeaux, Alexandra, Mateo, Mathieu, Carnec, Xavier, Schaeffer, Justine, Picard, Caroline, Barrot, Laura, Barron, Stéphane, Vallve, Audrey, Duthey, Aurélie, Jacquot, Frédéric, Boehringer, Cathy, Jouvion, Grégory, Pietrosemoli, Natalia, Legendre, Rachel, Dillies, Marie-Agnès, Allan, Richard, Legras-Lachuer, Catherine, Carbonnelle, Caroline, Raoul, Hervé, and Baize, Sylvain
- Published
- 2021
- Full Text
- View/download PDF
7. Fatal Case of Lassa Fever, Bangolo District, Cote d'Ivoire, 2015
- Author
-
Mateo, Mathieu, Picard, Caroline, Sylla, Yahaya, Kamo, Emilie, Odegue, Danielle, Journeaux, Alexandra, Kan, Stephane Kouassi, Money, Marcelle, Coulibaly, David N'Golo, Koffi, Eugene, Meite, Souleymane, Akran, Veronique, Kadjo, Herve, Adjogoua, Edgard, Kakou, Solange N'Gazoa, Baize, Sylvain, and Dosso, Mireille
- Subjects
Lassa fever -- Analysis ,Rural areas ,Health - Abstract
Lassa fever is endemic to western Africa. Nigeria, Guinea, Sierra Leone, and Liberia regularly have outbreaks of Lassa fever, mostly during the first few months of the year, corresponding to [...]
- Published
- 2019
- Full Text
- View/download PDF
8. Novel Antiviral Molecules against Ebola Virus Infection
- Author
-
Collados Rodríguez, Mila, primary, Maillard, Patrick, additional, Journeaux, Alexandra, additional, Komarova, Anastassia V., additional, Najburg, Valérie, additional, David, Raul-Yusef Sanchez, additional, Helynck, Olivier, additional, Guo, Mingzhe, additional, Zhong, Jin, additional, Baize, Sylvain, additional, Tangy, Frédéric, additional, Jacob, Yves, additional, Munier-Lehmann, Hélène, additional, and Meurs, Eliane F., additional
- Published
- 2023
- Full Text
- View/download PDF
9. Immunogenicity, safety and tolerability of a recombinant measles-vectored Lassa vaccine: A randomised, placebo-controlled, first-in-human trial
- Author
-
Tschismarov, Roland, van Damme, Pierre, Germain, Clara, De Coster, Ilse, Mateo, Mathieu, Reynard, Stephanie, Journeaux, Alexandra, Tomberger, Yvonne, Withanage, Kanchanamala, Haslwanter, Denise, Terler, Katherine, Schrauf, Sabrina, Muellner, Matthias, Tauber, Erich, Ramsauer, Katrin, Baize, Sylvain, Themis Bioscience GmbH, University of Antwerp (UA), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Biologie des Infections Virales Émergentes - Biology of Emerging Viral Infections (UBIVE), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité)
- Subjects
safety ,phase 1 ,vaccine ,[SDV]Life Sciences [q-bio] ,measles-vectored ,Human medicine ,General Medicine ,live-attenuated ,immunogenicity ,Lassa virus ,first in man ,placebo-controlled clinical trial - Abstract
International audience; BackgroundLassa fever is a substantial health burden in west Africa. We evaluated the safety, tolerability, and immunogenicity of a recombinant, live-attenuated, measles-vectored Lassa fever vaccine candidate (MV-LASV).MethodsThis first-in-human phase 1 trial—consisting of an open-label dose-escalation stage and an observer-blinded, randomised, placebo-controlled treatment stage—was conducted at a single site at the University of Antwerp, Antwerp, Belgium, and involved healthy adults aged 18–55 years. Participants in the dose-escalation stage were sequentially assigned to a low-dose group (two intramuscular doses of MV-LASV at 2 × 104 times the median tissue culture infectious dose) or a high-dose group (two doses at 1 × 105 times the median tissue culture infectious dose). Participants in the double-blinded treatment stage were randomly assigned in a 2:2:1 ratio to receive low dose, high dose, or placebo. The primary endpoint was the rate of solicited and unsolicited adverse events up to study day 56 and was assessed in all participants who received at least one dose of investigational product. The trial is registered with ClinicalTrials.gov, NCT04055454, and the European Union Drug Regulating Authorities Clinical Trials Database, 2018-003647-40, and is complete.FindingsBetween Sept 26, 2019, and Jan 20, 2020, 60 participants were enrolled and assigned to receive placebo (n=12) or MV-LASV (n=48). All 60 participants received at least one study treatment. Most adverse events occurred during the treatment phase, and frequencies of total solicited or unsolicited adverse events were similar between treatment groups, with 96% of participants in the low-dose group, 100% of those in the high-dose group, and 92% of those in the placebo group having any solicited adverse event (p=0·6751) and 76% of those in the low-dose group, 70% of those in the high-dose group, and 100% of those in the placebo group having any unsolicited adverse event (p=0·1047). The only significant difference related to local solicited adverse events, with higher frequencies observed in groups receiving MV-LASV (24 [96%] of 25 participants in the low-dose group; all 23 [100%] participants in the high-dose group) than in the placebo group (6 [50%] of 12 participants; p=0·0001, Fisher-Freeman-Halton test). Adverse events were mostly of mild or moderate severity, and no serious adverse events were observed. MV-LASV also induced substantial concentrations of LASV-specific IgG (geometric mean titre 62·9 EU/ml in the low-dose group and 145·9 EU/ml in the high-dose group on day 42).InterpretationMV-LASV showed an acceptable safety and tolerability profile, and immunogenicity seemed to be unaffected by pre-existing immunity against the vector. MV-LASV is therefore a promising candidate for further development.FundingCoalition for Epidemic Preparedness Innovations.
- Published
- 2023
- Full Text
- View/download PDF
10. Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys
- Author
-
Mateo, Mathieu, Hortion, Jimmy, Perthame, Emeline, Picard, Caroline, Reynard, Stéphanie, Journeaux, Alexandra, Germain, Clara, Carnec, Xavier, Baillet, Nicolas, Borges-Cardoso, Virginie, Pietrosemoli, Natalia, Vallve, Audrey, Barron, Stéphane, Jourjon, Ophélie, Lacroix, Orianne, Duthey, Aurélie, Dirheimer, Manon, Daniau, Maïlys, Legras-Lachuer, Catherine, Jouvion, Gregory, Carbonnelle, Caroline, Raoul, Hervé, Baize, Sylvain, Biologie des Infections Virales Émergentes - Biology of Emerging Viral Infections (UBIVE), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Laboratoire P4 - Jean Mérieux, Centre Européen de Virologie/Immunologie-Institut National de la Santé et de la Recherche Médicale (INSERM), ViroScan3D SAS [Trévoux, France], Dynamic Microbiology - EA 7380 (DYNAMIC), École nationale vétérinaire - Alfort (ENVA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université Paris-Est (UPE)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), MATEO, MATHIEU, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris]-Université Paris Cité (UPCité), and Institut Pasteur [Paris]-Université Paris Cité (UPCité)
- Subjects
Microbiology (medical) ,cynomolgus monkeys ,Immunology ,viral hemorrhagic fevers ,MESH: Lassa Fever ,Virus Replication ,[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity ,Microbiology ,Lassa Fever ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Animals ,Humans ,MESH: Animals ,Lassa virus ,[SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunity ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,MESH: Humans ,pathogenesis ,MESH: Virus Replication ,MESH: Lassa virus ,immune responses ,Macaca fascicularis ,Infectious Diseases ,MESH: Macaca fascicularis ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Parasitology - Abstract
We thank P. Regnard, P.H. Moreau, and L. Fellmann (SILABE, Strasbourg) for medical care given to the monkeys. We thank S. Mundweiller, S. Godard, E. Moissonnier, D. Thomas, S. Mely, B. Labrosse, D. Pannetier, and C. Leculier (P4 INSERM–Jean Merieux, US003, INSERM) for assistance in conducting the BSL-4 experiments. We thank M-A Dillies (HUB, Institut Pasteur) for helpful discussions. We thank G. Fourcaud and B. Lafoux (UBIVE, CIRI, Institut Pasteur) for technical help. We also thank L. Branco (Zalgen Labs) for providing recombinant proteins. We are grateful to the Coalition for Epidemic Preparedness and Innovations (R. Hatchett, G. Thiry, and M. Saville) and C. Gerke (Department of Innovation Development, Institut Pasteur) for invaluable support.; International audience; The area of Lassa virus (LASV) circulation is expanding, with the emergence of highly pathogenic new LASV lineages. Benin recently became an endemic country for LASV and has seen the emergence of a new LASV lineage (VII). The first two outbreaks in 2014 and 2016 showed a relatively high mortality rate compared to other outbreaks. We infected cynomolgus monkeys with two strains belonging to lineage II and lineage VII that were isolated from deceased patients during the 2016 outbreak in Benin. The lineage VII strain (L7) caused uniform mortality. Death was associated with uncontrolled viral replication, unbalanced inflammatory responses characterized by increased concentrations of pro- and anti-inflammatory mediators, and the absence of efficient immune responses, resembling the pathogenesis associated with the prototypic Josiah strain in monkeys. The lineage II strain (L2) showed apparently lower virulence than its counterpart, with a prolonged time to death and a lower mortality rate. Prolonged survival was associated with better control of viral replication, a moderate inflammatory response, and efficient T-cell responses. Transcriptomic analyses also highlighted important differences in the immune responses associated with the outcome. Both strains caused strong inflammation in several organs. Notably, meningitis and encephalitis were observed in the cerebral cortex and cerebellum in all monkeys, independently of the outcome. Due to their apparently high pathogenicity, emerging strains from lineage VII should be considered in preclinical vaccine testing. Lineage II would also be beneficial in pathogenesis studies to study the entire spectrum of Lassa fever severity.
- Published
- 2022
- Full Text
- View/download PDF
11. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains
- Author
-
Mateo, Mathieu, primary, Reynard, Stéphanie, additional, Journeaux, Alexandra, additional, Germain, Clara, additional, Hortion, Jimmy, additional, Carnec, Xavier, additional, Picard, Caroline, additional, Baillet, Nicolas, additional, Borges-Cardoso, Virginie, additional, Merabet, Othmann, additional, Vallve, Audrey, additional, Barron, Stéphane, additional, Jourjon, Ophélie, additional, Lacroix, Orianne, additional, Duthey, Aurélie, additional, Dirheimer, Manon, additional, Jouvion, Gregory, additional, Moreau, Pierre-Henri, additional, Fellmann, Lyne, additional, Carbonnelle, Caroline, additional, Raoul, Hervé, additional, Tangy, Frédéric, additional, and Baize, Sylvain, additional
- Published
- 2021
- Full Text
- View/download PDF
12. MyD88 in DNA Repair and Cancer Cell Resistance to Genotoxic Drugs
- Author
-
Kfoury, Alain, Corf, Katy Le, Sabeh, Rana El, Journeaux, Alexandra, Badran, Bassam, Hussein, Nader, Lebecque, Serge, Manié, Serge, Renno, Toufic, and Coste, Isabelle
- Published
- 2013
- Full Text
- View/download PDF
13. Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus
- Author
-
Yadouleton, Anges, primary, Picard, Caroline, additional, Rieger, Toni, additional, Loko, Frederic, additional, Cadar, Daniel, additional, Kouthon, Emile Cossi, additional, Job, Emmanuel Obolli, additional, Bankolé, Honoré, additional, Oestereich, Lisa, additional, Gbaguidi, Fernand, additional, Pahlman, Meike, additional, Becker-Ziaja, Beate, additional, Journeaux, Alexandra, additional, Pannetier, Delphine, additional, Mély, Stéphane, additional, Mundweiler, Stéphanie, additional, Thomas, Damien, additional, Kohossi, Leon, additional, Saizonou, Raoul, additional, Kakaï, Clement Glele, additional, Da Silva, Magloire, additional, Kossoubedie, Sonia, additional, Kakonku, André Lukusa, additional, M’Pelé, Pierre, additional, Gunther, Stephan, additional, Baize, Sylvain, additional, and Fichet-Calvet, Elisabeth, additional
- Published
- 2020
- Full Text
- View/download PDF
14. E3 Ligase ITCH Interacts with the Z Matrix Protein of Lassa and Mopeia Viruses and Is Required for the Release of Infectious Particles
- Author
-
Baillet, Nicolas, primary, Krieger, Sophie, additional, Carnec, Xavier, additional, Mateo, Mathieu, additional, Journeaux, Alexandra, additional, Merabet, Othmann, additional, Caro, Valérie, additional, Tangy, Frédéric, additional, Vidalain, Pierre-Olivier, additional, and Baize, Sylvain, additional
- Published
- 2019
- Full Text
- View/download PDF
15. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot
- Author
-
Mateo, Mathieu, primary, Reynard, Stéphanie, additional, Carnec, Xavier, additional, Journeaux, Alexandra, additional, Baillet, Nicolas, additional, Schaeffer, Justine, additional, Picard, Caroline, additional, Legras-Lachuer, Catherine, additional, Allan, Richard, additional, Perthame, Emeline, additional, Hillion, Kenzo-Hugo, additional, Pietrosemoli, Natalia, additional, Dillies, Marie-Agnès, additional, Barrot, Laura, additional, Vallve, Audrey, additional, Barron, Stéphane, additional, Fellmann, Lyne, additional, Gaillard, Jean-Charles, additional, Armengaud, Jean, additional, Carbonnelle, Caroline, additional, Raoul, Hervé, additional, Tangy, Frédéric, additional, and Baize, Sylvain, additional
- Published
- 2019
- Full Text
- View/download PDF
16. Autophagy Promotes Infectious Particle Production of Mopeia and Lassa Viruses
- Author
-
Baillet, Nicolas, primary, Krieger, Sophie, additional, Journeaux, Alexandra, additional, Caro, Valérie, additional, Tangy, Frédéric, additional, Vidalain, Pierre-Olivier, additional, and Baize, Sylvain, additional
- Published
- 2019
- Full Text
- View/download PDF
17. Immune parameters and outcomes during Ebola virus disease
- Author
-
Reynard, Stéphanie, primary, Journeaux, Alexandra, additional, Gloaguen, Emilie, additional, Schaeffer, Justine, additional, Varet, Hugo, additional, Pietrosemoli, Natalia, additional, Mateo, Mathieu, additional, Baillet, Nicolas, additional, Laouenan, Cédric, additional, Raoul, Hervé, additional, Mullaert, Jimmy, additional, and Baize, Sylvain, additional
- Published
- 2019
- Full Text
- View/download PDF
18. Human Dendritic Cells Infected with the Nonpathogenic Mopeia Virus Induce Stronger T-Cell Responses than Those Infected with Lassa Virus
- Author
-
Pannetier, Delphine, primary, Reynard, Stéphanie, additional, Russier, Marion, additional, Journeaux, Alexandra, additional, Tordo, Noël, additional, Deubel, Vincent, additional, and Baize, Sylvain, additional
- Published
- 2011
- Full Text
- View/download PDF
19. Human Langerhans Cells Are More Efficient Than CD14−CD1c+ Dermal Dendritic Cells at Priming Naive CD4+ T Cells
- Author
-
Furio, Laetitia, primary, Briotet, Isabelle, additional, Journeaux, Alexandra, additional, Billard, Hermine, additional, and Péguet-Navarro, Josette, additional
- Published
- 2010
- Full Text
- View/download PDF
20. Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus Monkeys
- Author
-
Baize, Sylvain, primary, Marianneau, Philippe, additional, Loth, Philippe, additional, Reynard, Stéphanie, additional, Journeaux, Alexandra, additional, Chevallier, Michèle, additional, Tordo, Noël, additional, Deubel, Vincent, additional, and Contamin, Hugues, additional
- Published
- 2009
- Full Text
- View/download PDF
21. Fatal Lassa fever in cynomolgus monkeys is associated with systemic viral dissemination and inflammation.
- Author
-
Hortion, Jimmy, Perthame, Emeline, Lafoux, Blaise, Soyer, Laura, Reynard, Stéphanie, Journeaux, Alexandra, Germain, Clara, Lopez-Maestre, Hélène, Pietrosemoli, Natalia, Baillet, Nicolas, Croze, Séverine, Rey, Catherine, Legras-Lachuer, Catherine, and Baize, Sylvain
- Abstract
The pathogenesis of Lassa fever has not yet been fully deciphered, particularly as concerns the mechanisms determining whether acute infection is controlled or leads to catastrophic illness and death. Using a cynomolgus monkey model of Lassa virus (LASV) infection reproducing the different outcomes of the disease, we performed histological and transcriptomic studies to investigate the dynamics of LASV infection and the immune mechanisms associated with survival or death. Lymphoid organs are an early major reservoir for replicating virus during Lassa fever, with LASV entering through the cortical sinus of draining lymph nodes regardless of disease outcome. However, subsequent viral tropism varies considerably with disease severity, with viral dissemination limited almost entirely to lymphoid organs and immune cells during nonfatal Lassa fever. By contrast, the systemic dissemination of LASV to all organs and diverse cell types, leading to infiltrations with macrophages and neutrophils and an excessive inflammatory response, is associated with a fatal outcome. These results provide new insight into early viral dynamics and the host response to LASV infection according to disease outcome. Author summary: Lassa fever, induced by Lassa virus, is a viral hemorrhagic fever of great concern as it is endemic to a large part of Africa, with tens of thousands of cases per year, and there is no effective treatment or licensed vaccine. Lassa virus can be handled only in biosafety level 4 facilities and access to patients is limited. As a result, little is known about the pathogenesis of this severe disease. Non-human primates, and macaques in particular, are the most relevant animal models for studies of this disease. We previously developed a cynomolgus monkey model reproducing the different outcomes of Lassa fever observed in humans: limited clinical signs and recovery versus catastrophic illness and death. Here, we use this model to investigate further the dynamics of Lassa virus dissemination, cell tropism in different organs, and host response to infection. Our findings demonstrate that cell tropism and viral dissemination differ considerably between outcomes, underlying the different host responses to Lassa virus infection and differences in severity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. E3 Ligase ITCH Interacts with the Z Matrix Protein of Lassa and Mopeia Viruses and Is Required for the Release of Infectious Particles.
- Author
-
Baillet, Nicolas, Krieger, Sophie, Carnec, Xavier, Mateo, Mathieu, Journeaux, Alexandra, Merabet, Othmann, Caro, Valérie, Tangy, Frédéric, Vidalain, Pierre-Olivier, and Baize, Sylvain
- Subjects
EXTRACELLULAR matrix proteins ,UBIQUITINATION ,LYMPHOCYTIC choriomeningitis virus ,ARENAVIRUS diseases ,ITCHING ,UBIQUITIN ligases - Abstract
Lassa virus (LASV) and Mopeia virus (MOPV) are two closely related, rodent-born mammarenaviruses. LASV is the causative agent of Lassa fever, a deadly hemorrhagic fever endemic in West Africa, whereas MOPV is non-pathogenic in humans. The Z matrix protein of arenaviruses is essential to virus assembly and budding by recruiting host factors, a mechanism that remains partially defined. To better characterize the interactions involved, a yeast two-hybrid screen was conducted using the Z proteins from LASV and MOPV as a bait. The cellular proteins ITCH and WWP1, two members of the Nedd4 family of HECT E3 ubiquitin ligases, were found to bind the Z proteins of LASV, MOPV and other arenaviruses. The PPxY late-domain motif of the Z proteins is required for the interaction with ITCH, although the E3 ubiquitin-ligase activity of ITCH is not involved in Z ubiquitination. The silencing of ITCH was shown to affect the replication of the old-world mammarenaviruses LASV, MOPV, Lymphocytic choriomeningitis virus (LCMV) and to a lesser extent Lujo virus (LUJV). More precisely, ITCH was involved in the egress of virus-like particles and the release of infectious progeny viruses. Thus, ITCH constitutes a novel interactor of LASV and MOPV Z proteins that is involved in virus assembly and release. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. Human Langerhans Cells Are More Efficient Than CD14−CD1c+ Dermal Dendritic Cells at Priming Naive CD4+ T Cells.
- Author
-
Furio, Laetitia, Briotet, Isabelle, Journeaux, Alexandra, Billard, Hermine, and Péguet-Navarro, Josette
- Subjects
- *
SKIN , *LANGERHANS cells , *T cells , *EPIDERMIS , *MOLECULES , *CYTOKINES - Abstract
Few data are available regarding the role of human skin dendritic cells (DCs) in driving T-cell responses. In this study we analyzed the relative capacity of Langerhans cells (LCs) and dermal CD14−CD1c+ DCs (DDCs) to trigger naive CD4+ T-cell proliferation and differentiation. DC subsets were purified after a 2-day migration from epidermis and dermis of the same skin sample. Migratory LCs showed far more activated phenotype than CD1c+DDCs and distinct expression of new molecules of the B7 family; when compared with LCs, CD1c+DDCs showed higher PD-L1 and lower inducible co-stimulator ligand (ICOS-L) expression. As expected, CD1c+DDCs showed lower allostimulatory property than LCs, a process that was partly reversed by anti-PD-L1 mAb. LCs were significantly more efficient than CD1c+DDCs at inducing allogeneic naive CD4+ T cells to secrete both T helper cell 1 (Th1; IFN-γ and tumor necrosis factor-α ) and Th2 (IL-4 and IL-5) cytokines. Moreover, anti-PD-L1 mAb increased the production of IFN-γ by both LC- and CD1c+DDC-stimulated T cells. Globally, these results argue for a preponderant role of human LCs in inducing naive CD4+ T-cell priming. Low expression of co-stimulatory molecules together with high expression of PD-L1 might limit the efficiency of CD1c+DDCs at inducing naive CD4+ T-cell proliferation and secretion of cytokines. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
24. Detection of Crimean-Congo haemorrhagic fever virus in Hyalomma marginatum ticks, southern France, May 2022 and April 2023.
- Author
-
Bernard C, Joly Kukla C, Rakotoarivony I, Duhayon M, Stachurski F, Huber K, Giupponi C, Zortman I, Holzmuller P, Pollet T, Jeanneau M, Mercey A, Vachiery N, Lefrançois T, Garros C, Michaud V, Comtet L, Despois L, Pourquier P, Picard C, Journeaux A, Thomas D, Godard S, Moissonnier E, Mely S, Sega M, Pannetier D, Baize S, and Vial L
- Subjects
- Humans, Animals, Cattle, Horses, Zoonoses, France epidemiology, Hemorrhagic Fever Virus, Crimean-Congo genetics, Ticks, Hemorrhagic Fever, Crimean diagnosis, Hemorrhagic Fever, Crimean epidemiology, Hemorrhagic Fever, Crimean veterinary, Ixodidae
- Abstract
Crimean-Congo haemorrhagic fever (CCHF), a potentially severe zoonotic viral disease causing fever and haemorrhagic manifestations in humans. As the Crimean-Congo haemorrhagic fever virus (CCHFV) has been detected in ticks in Spain and antibodies against the virus in ruminant sera in Corsica, it was necessary to know more about the situation in France. In 2022-2023, CCHFV was detected in 155 ticks collected from horses and cattle in southern France.
- Published
- 2024
- Full Text
- View/download PDF
25. Human langerhans cells are more efficient than CD14(-)CD1c(+) dermal dendritic cells at priming naive CD4(+) T cells.
- Author
-
Furio L, Briotet I, Journeaux A, Billard H, and Péguet-Navarro J
- Subjects
- Antigens, CD metabolism, Antigens, CD1 metabolism, B7-H1 Antigen, CD40 Ligand pharmacology, Cell Differentiation immunology, Cell Division immunology, Cell Movement immunology, Down-Regulation immunology, Glycoproteins metabolism, Humans, Immunophenotyping, Interferon-gamma pharmacology, Isoantigens immunology, Langerhans Cells cytology, Langerhans Cells metabolism, Lipopolysaccharide Receptors metabolism, Lymphocyte Activation drug effects, Lymphocyte Activation immunology, Th1 Cells cytology, Th2 Cells cytology, Cell Communication immunology, Langerhans Cells immunology, Th1 Cells immunology, Th2 Cells immunology
- Abstract
Few data are available regarding the role of human skin dendritic cells (DCs) in driving T-cell responses. In this study we analyzed the relative capacity of Langerhans cells (LCs) and dermal CD14(-)CD1c(+) DCs (DDCs) to trigger naive CD4(+) T-cell proliferation and differentiation. DC subsets were purified after a 2-day migration from epidermis and dermis of the same skin sample. Migratory LCs showed far more activated phenotype than CD1c(+)DDCs and distinct expression of new molecules of the B7 family; when compared with LCs, CD1c(+)DDCs showed higher PD-L1 and lower inducible co-stimulator ligand (ICOS-L) expression. As expected, CD1c(+)DDCs showed lower allostimulatory property than LCs, a process that was partly reversed by anti-PD-L1 mAb. LCs were significantly more efficient than CD1c(+)DDCs at inducing allogeneic naive CD4(+) T cells to secrete both T helper cell 1 (Th1; IFN-gamma and tumor necrosis factor-alpha ) and Th2 (IL-4 and IL-5) cytokines. Moreover, anti-PD-L1 mAb increased the production of IFN-gamma by both LC- and CD1c(+)DDC-stimulated T cells. Globally, these results argue for a preponderant role of human LCs in inducing naive CD4(+) T-cell priming. Low expression of co-stimulatory molecules together with high expression of PD-L1 might limit the efficiency of CD1c(+)DDCs at inducing naive CD4(+) T-cell proliferation and secretion of cytokines.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.